Montelukast Vir (Montelukast Sodium)

Montelukast selectively antagonizes the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from triggering bronchoconstriction and inflammatory processes in the respiratory tract. This action reduces airway narrowing and allergic inflammation.

The dose of Montelukast Vir is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and clinical response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Montelukast during pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the medication.

To place an order, submit an enquiry on the Montelukast Vir product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients who prefer oral therapy or have aspirin‑exacerbated respiratory disease, though inhaled steroids remain first‑line for many asthma patients.

Montelukast Vir should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture and direct sunlight to maintain stability throughout its shelf life.

Montelukast Vir is taken orally as a tablet. The tablet should be swallowed whole with water, and it can be taken with or without food according to the prescriber’s guidance.

Serious adverse events, though rare, include angioedema, severe skin reactions such as Stevens‑Johnson syndrome, and neuropsychiatric effects like depression or suicidal thoughts. Patients should seek immediate medical attention if they experience swelling of the face or throat, rash with blistering, or significant mood changes.

Montelukast Vir should be avoided in individuals with known hypersensitivity to montelukast or any of its excipients. Caution is also advised for patients with severe hepatic impairment, and it is not recommended for use in children under the age approved for the specific formulation.